Literature DB >> 19443579

Value of SPECT/CT for detection and anatomic localization of sentinel lymph nodes before laparoscopic sentinel node lymphadenectomy in prostate carcinoma.

Lenka Vermeeren1, Renato A Valdés Olmos, Wim Meinhardt, Axel Bex, Henk G van der Poel, Wouter V Vogel, Ferida Sivro, Cees A Hoefnagel, Simon Horenblas.   

Abstract

UNLABELLED: Laparoscopic evaluation of sentinel nodes is useful for staging prostate cancer, but preoperative localization of deep abdominal sentinel nodes with planar lymphoscintigraphy is difficult. We evaluated the value of SPECT/CT for detecting and localizing sentinel nodes in prostate cancer.
METHODS: (99m)Tc-nanocolloid was injected peri- and intratumorally, guided by transrectal ultrasonography, in 46 patients with prostate cancer of intermediate prognosis. Patients underwent planar imaging after 15 min and 2 h, SPECT/CT after 2 h, and laparoscopic sentinel node lymphadenectomy on the same day. SPECT was fused with CT and analyzed using 2-dimensional orthogonal slicing and 3-dimensional volume rendering. We evaluated the number of extra sentinel nodes found by SPECT/CT, the number of sentinel nodes found by SPECT/CT outside the area of the extended pelvic lymphadenectomy, and the anatomic information provided by SPECT/CT. Furthermore, we classified the value of the additional SPECT/CT images into 3 categories (no advantage, presumable advantage, and definite advantage) according to the extra anatomic information given and whether additional sentinel nodes were found by SPECT/CT.
RESULTS: The patients had a mean age of 64 y (range, 53-74 y) and received a mean injected dose of 218 MBq (range, 147-286 MBq). The sentinel node visualization rate was 91% (42 patients) for planar imaging and 98% (45 patients) for SPECT/CT. In 29 of the 46 patients (63%), SPECT/CT revealed additional sentinel nodes (especially lymph nodes near the injection area) not seen on planar imaging. In 7 patients, those additional sentinel nodes were positive for metastasis (being the exclusive metastatic sentinel node in 4 patients). Overall, 15 patients (33%) had positive sentinel nodes. Sentinel nodes outside the area of extended pelvic lymphadenectomy were found in 16 patients (35%), whereas in 56% of these patients those nodes were not seen on planar imaging. Performing SPECT/CT had no advantage in 13% of the patients, a presumable advantage in 24%, and a definite advantage in 63%. Urologic surgeons used the SPECT/CT images to guide their trocar insertion sites and sentinel node finding with the probe.
CONCLUSION: More sentinel nodes can be detected with SPECT/CT than with planar imaging alone. In comparison with planar imaging, SPECT/CT especially reveals extra sentinel nodes near the prostate and outside the area of the extended pelvic lymphadenectomy. Furthermore, the modality provides useful additional information about the anatomic location of sentinel nodes within and outside the pelvic area, leading to improved intraoperative sentinel node identification.

Entities:  

Mesh:

Year:  2009        PMID: 19443579     DOI: 10.2967/jnumed.108.060673

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  21 in total

Review 1.  SPECT/CT and tumour imaging.

Authors:  Gad Abikhzer; Zohar Keidar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-29       Impact factor: 9.236

Review 2.  Individualized image-based lymph node irradiation for prostate cancer.

Authors:  Hanneke J M Meijer; Oscar A Debats; Emile N J Th van Lin; Marco van Vulpen; J Alfred Witjes; Wim J G Oyen; Jelle O Barentsz; Johannes H A M Kaanders
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

Review 3.  Imaging the lymphatic system.

Authors:  Lance L Munn; Timothy P Padera
Journal:  Microvasc Res       Date:  2014-06-21       Impact factor: 3.514

4.  Positron lymphography: multimodal, high-resolution, dynamic mapping and resection of lymph nodes after intradermal injection of 18F-FDG.

Authors:  Daniel L J Thorek; Diane S Abou; Bradley J Beattie; Rachel M Bartlett; Ruimin Huang; Pat B Zanzonico; Jan Grimm
Journal:  J Nucl Med       Date:  2012-08-07       Impact factor: 10.057

Review 5.  Melanoma and nuclear medicine.

Authors:  Andrés Perissinotti; Sergi Vidal-Sicart; Omgo Nieweg; Renato Valdés Olmos
Journal:  Melanoma Manag       Date:  2014-09-05

6.  Feasibility of sentinel node detection in renal cell carcinoma: a pilot study.

Authors:  Axel Bex; Lenka Vermeeren; Geraldine de Windt; Warner Prevoo; Simon Horenblas; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-29       Impact factor: 9.236

7.  Lymphatic drainage from the treated versus untreated prostate: feasibility of sentinel node biopsy in recurrent cancer.

Authors:  Lenka Vermeeren; Willem Meinhardt; Henk G van der Poel; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-09       Impact factor: 9.236

8.  Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma.

Authors:  Caroline Rousseau; Thierry Rousseau; Boumédiène Bridji; Amandine Pallardy; Jacques Lacoste; Loïc Campion; Aude Testard; Geneviève Aillet; Ayat Mouaden; Chantal Curtet; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-16       Impact factor: 9.236

9.  The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects.

Authors:  Hojjat Ahmadzadehfar; Marianne Muckle; Amir Sabet; Kai Wilhelm; Christiane Kuhl; Kim Biermann; Torjan Haslerud; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

10.  Optimizing the colloid particle concentration for improved preoperative and intraoperative image-guided detection of sentinel nodes in prostate cancer.

Authors:  Lenka Vermeeren; Sara H Muller; Willem Meinhardt; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.